Discovery of 2-[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia

Cited by (232)

Items 101–200 of 232

1. Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders
   Su-Wen Lin, Shengjian Huang, Zhou Deng, Yu Zhang, Lin Huang, Yanyi Wu, Shuyan Lv, Zhiyi Wang, Ning Huang, Lan Wang et al. · 2023 · Frontiers in Endocrinology
2. Resmetirom and Thyroid Hormone Receptor‐Targeted Treatment for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD)
   Chang‐Hai Liu, Qing‐Min Zeng, Teng‐Yue Hu, Yu Huang, Yongfeng Song, Haixia Guan, Don C. Rockey, Hong Chai Tang, Sheyu Li · 2025 · Portal hypertension & cirrhosis
3. Selective Agonists of Thyroid Hormone Receptor Beta: Promising Tools for the Treatment of Nonalcoholic Fatty Liver Disease
   Sun Wook Cho · 2024 · Endocrinology and Metabolism
4. New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024
   Shu Wei Wong, Yong‐Yu Yang, Hui Chen, Li Huitong Xie, Xizhong Shen, Ning‐Ping Zhang, Jian Huang Wu · 2025 · Acta Pharmacologica Sinica
5. Non-alcoholic fatty liver disease: digest 2021
   Кролевец Татьяна Сергеевна, V.A. Livzan · 2021 · Russian Journal of Evidence-Based Gastroenterology
6. Mouse models of nonalcoholic steatohepatitis and their application to new drug development
   Huy Hieu Phung, Chang Hoon Lee · 2022 · Archives of Pharmacal Research
7. Advancements in Understanding and Treating NAFLD: A Comprehensive Review of Metabolic-Associated Fatty Liver Disease and Emerging Therapies
   Jacob Beiriger, Kashyap Chauhan, Adnan Khan, Taha Shahzad, Natalia Salinas Parra, Peter G. Y. Zhang, Sarah Chen, Tuan Anh Nguyen, Brian M. Yan, John Bruckbauer et al. · 2023 · Livers
8. Resmetirom
   Terri L. Levien, Danial E. Baker · 2024 · Hospital Pharmacy
9. Expanding diagnostic and therapeutic horizons for MASH: Comparison of the latest and conventional therapeutic approaches
   Georgia Anastasiou, Konstantinos Stefanakis, Michael A. Hill, Christos Socrates Mantzoros · 2024 · Metabolism
10. Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
    Sven Francque, Vlad Ratziu · 2023 · Clinics in Liver Disease
11. Classification of thyroid hormone receptor agonists and antagonists using statistical learning approaches
    Fangfang Wang, Jinyi Xing · 2018 · Molecular Diversity
12. Beneficial effects of MGL ‐3196 and BAM15 combination in a mouse model of fatty liver disease
    Mingyan Zhou, Catherine Li, Frances L. Byrne, Calum S Vancuylenburg, Ellen M. Olzomer, Adam Hargreaves, Lindsay E. Wu, Nicholas Adam Shackel, Webster L. Santos, Kyle L. Hoehn · 2024 · Acta Physiologica
13. Treatment of IL-18-binding protein biologics suppresses fibrotic progression in metabolic dysfunction-associated steatohepatitis
    Dong-Hyun Kim, Gi Hong Choi, Eun-Bi Song, Han Na Lee, Jae Kyeom Kim, Young‐Saeng Jang, JinJoo Park, Susan Chi, Jaekyu Han, Dongyoon Kim et al. · 2025 · Cell Reports Medicine
14. CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models
    Shengjian Huang, Zhou Deng, Wei Wang, Guoqiang Liao, Yiru Zhao, Hua Zhong, Qian Zhang, Jing Liu, Xuhua Mao, Beizhong Chen et al. · 2023 · International Journal of Endocrinology
15. Resmetirom and semaglutide in metabolic dysfunction-associated steatohepatitis (MASH): a comparative perspective
    Ralf Weiskirchen · 2025 · Exploration of Drug Science
16. Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
    Jingwei Li, Ruixian Chen, Jinhang Zhang, Jinhan He, Yuxi Wang, Yanping Li · 2026 · Journal of Medicinal Chemistry
17. Validation of PAS Kinase, a Regulator of Hepatic Fatty Acid and Triglyceride Synthesis, as a Therapeutic Target for Nonalcoholic Steatohepatitis
    Wojciech Swiatek, K. Mark Parnell, G. Allen Nickols, Bruce F. Scharschmidt, Jared P. Rutter · 2020 · Hepatology Communications
18. T3 and glucose increase expression of phosphoenolpyruvate carboxykinase (PCK1) leading to increased β-cell proliferation
    Liora S. Katz, Carmen Argmann, Luca Lambertini, Donald K. Scott · 2022 · Molecular Metabolism
19. Resmetirom in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis
    Fares Jamal, Amani Elshaer, Nour B. Odeh, Mayar H. Alatout, Tala B. Shahin, Astin R Worden, Hashem N. Albunni, Blanca C Lizaola-Mayo, C. Jayasekera, D. Chascsa et al. · 2025 · Life
20. Resmetirom, the first FDA-approved drug for MASH: From drug discovery and action mechanisms to clinical trials
    Jiaman Liu, Fenghua Yang, Boya Gao, Lihui Yang, Yutong Cao, Yun Zhou · 2025 · Archives of Pharmacal Research
21. Review article: the impact of liver‐directed therapies on the atherogenic risk profile in non‐alcoholic steatohepatitis
    Margery A. Connelly, Jonathan Velez Rivera, John R. Guyton, Mohammad Shadab Siddiqui, Arun Jayant Sanyal · 2020 · Alimentary Pharmacology & Therapeutics
22. Microsomal triglyceride transfer protein inhibitor lomitapide-induced liver toxicity is ameliorated by Triiodothyronine treatment following improved bile homeostasis and β-oxidation
    VISHAL G. PATEL, Amit Arvind Joharapurkar, Samadhan Govind Kshirsagar, Maulik S. Patel, Hiren Patel, Hardikkumar H. Savsani, Mukul Rameshchandra Jain · 2021 · Toxicology and Applied Pharmacology
23. Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?
    Paulina Vidal‐Cevallos, Norberto Carlos Chávez-Tapia · 2024 · Med
24. FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
    Muhammad Mazhar Azam, Sameen Mukhtar, Muhammad Haris, Fatima Laique, Suhaina Amir, Mubashir Mohiuddin, Bibek Giri · 2024 · Exploration of Drug Science
25. FibroScan Discordance With Liver Biopsy Significantly Overestimates Advanced Fibrosis and Cirrhosis in MASLD Subjects With Class 3 Obesity
    Jena Velji-Ibrahim, Jordan S. Woodard, Jay Alden, Gary A. Abrams · 2025 · Journal of Clinical Gastroenterology
26. Molecular Dynamic Simulation To Reveal the Mechanism Underlying MGL-3196 Resistance to Thyroxine Receptor Beta
    Yi Lu, Chun Chen, Deyi Zhuang, Qian Liling · 2024 · ACS Omega
27. Basic science to clinical trials in non-alcoholic fatty liver disease and alcohol-related liver disease: collaboration with industry
    Amon Asgharpour, Amreen M. Dinani, Scott L. Friedman · 2020 · Translational Gastroenterology and Hepatology
28. 1,2,4-Triazines and Their Benzo Derivatives
    Sergey M. Ivanov · 2021 · Elsevier eBooks
29. Of mice and men: Why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?
    Chrysoula Boutari, Stergios A. Pοlyzos, Christos Socrates Mantzoros · 2019 · Metabolism
30. Biochemical basis and therapeutic potential of mitochondrial uncoupling in cardiometabolic syndrome
    Bernardo Gindri dos Santos, Niki F. Brisnovali, Leigh Goedeke · 2024 · Biochemical Journal
31. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
    Hyeyeon Hong, Jonggi Choi · 2024 · Korean Journal of Gastroenterology
32. Pyridazinone: A privileged scaffold for synthetic and biomedical applications
    Babita Kushwaha, Narva Deshwar Kushwaha, Baji Baba Shaik, Balakumar Chandrasekaran, Vincent A. Obakachi, Sithabile Mokoena, Sachin Balaso Mohite, Rajshekhar V. Karpoormath · 2024 · Journal of Molecular Structure
33. Thyroid Hormone Analogs: Recent Developments
    Matthijs Freund, Ferdy S. van Geest, Stefan Groeneweg, Ferdy S. van Geest, W. Edward Visser · 2025 · Thyroid
34. Resmetirom: The First FDA-Approved Drug for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with a Perspective on Precision Medicine
    Fengshuo Zhang, Yicong Meng, Bohan Zhao, Ziang Li, Mengran Han, Ming Li, Yun Zhou · 2025 · Clinical Drug Investigation
35. Thyroid receptor β: A promising target for developing novel anti-androgenetic alopecia drugs
    Jia Zhi, Feifan Li, Xiaoying Jiang, Renren Bai · 2024 · Drug Discovery Today
36. Selective thyroid hormone receptor β agonists with oxadiazolone acid isosteres
    Thorsten A. Kirschberg, Christopher T. Jones, Ying‐zi Xu, Martijn Fenaux, Randall L. Halcomb, Yujin Wang, Kevin M. Klucher · 2020 · Bioorganic & Medicinal Chemistry Letters
37. A comprehensive review of small molecule drugs approved by the FDA in 2025: advance and prospect
    Yi‐Ru Bai, Ruifang Li, Xinhui Zhang, Dong‐Jie Seng, Ying Xu, Sai‐Yang Zhang, Shuo Yuan · 2026 · Journal of Enzyme Inhibition and Medicinal Chemistry
38. ECM remodeling in hypothyroidism-associated MAFLD: mechanisms, clinical relevance, and therapeutic targets
    Tianzhen Wang, Liyun Duan, Beiying Zhao, Jingbin Zhang, Yongjiang Yu, Jin-Yue Zhao · 2025 · Frontiers in Immunology
39. Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
    Seungchan Choi, Jin‐Seok Jung, Yie‐sung Seo, Sungmin Song, Jeehye Ham, Hannah Chung, Yousef Ramadan, Kangchan Choi · 2026 · Journal of Cellular and Molecular Medicine
40. A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy
    Monan Liu, Ye Ma, Wai San Cheang, Zhengding Su, Suowen Xu · 2026 · Molecular Therapy
41. Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential
    Raj H. Patel, Charmy Parikh, Henil Upadhyay, Sneh Sonaiya, Parameswaran Ramnath, Shubham Singh, Umang Patel, Truptesh H. Kothari · 2024 · Cureus
42. Sex-Specific Effects of THRβ Signaling on Metabolic Responses to High Fat Diet in Mice
    Aruljothi Muralidharan, Gustavo A. Gomez, Chandrasekhar Kesavan, Sheila Pourteymoor, Destiney Larkin, William Tambunan, V. Franklin Sechriest, Subburaman Mohan · 2024 · Endocrinology
43. General Synthesis of 1-Aryl-6-azaisocytosines and Their Utilization for the Preparation of Related Condensed 1,2,4-Triazines
    František Zálešák, Jan Slouka, Jakub Stýskala · 2019 · Molecules
44. Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice
    Takumi Sugawara, Kosuke Hitaka, Mitsuharu Matsumoto, Sayuri Nakamura, Ryosuke Kobayashi, Hitoshi Kandori, Yasunori Nio · 2025 · Scientific Reports
45. Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    Laurens A. van Kleef, Maurice Stephan Michel, Naim Alkhouri, Willem Pieter Brouwer, Jörn Markus Schattenberg · 2026 · Drug Design Development and Therapy
46. MASLD and the cardiovascular-kidney-liver-metabolic syndrome
    Angeliki M. Angelidi, Chrysoula Boutari, Michail Kokkorakis, Konstantinos Stefanakis, Dimitri P. Mikhailidis, George Jacob, Christos Socrates Mantzoros · 2026 · Endocrine Reviews
47. A comprehensive review of small molecule drugs approved by the FDA in 2024: Advance and prospect
    Yi‐Ru Bai, Qing-Chuan Duan, Dong‐Jie Seng, Ying Xu, Hongbo Ren, Jie Zhang, Dandan Shen, Li Yang, Hong‐Min Liu, Shuo Yuan · 2025 · Chinese Chemical Letters
48. Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting
    Yi-Fang Li, Meina Zheng, Steven Limbara, Shanshan Zhang, Yutao Yu, Le Yu, Jian Jiao · 2024 · Journal of Clinical and Translational Hepatology
49. Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study
    Barbara Sjouke, Laura P. B. Elbers, Bregje van Zaane, John J.P. Kastelein, G. Kees Hovingh, Victor E. A. Gerdes · 2017 · Scientific Reports
50. Advances and Emerging Therapies in the Treatment of Non-alcoholic Steatohepatitis
    Brennan, Paul N, The University of Edinburgh, Centre for Regenerative Medicine, Edinburgh, UK, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK, Dillon, John F, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK, McCrimmon, Rory, NHS Tayside, Ninewells Hospital and Medical School, Dundee, UK, The University of Dundee, Department of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, Dundee, UK · 2022 · European Endocrinology
51. The thyroid-liver axis in MASLD: From metabolic control to clinical translation
    Yasmina Chouik, Cyrielle Caussy, Frank Tacke · 2026 · Med
52. Application of Bioisosteres in the Design and Discovery of FDA-Approved Drugs and Advanced Clinical Candidates
    Yong‐Jin Wu, Alyah F. Chmiel, Joanne J. Bronson · 2026 · Journal of Medicinal Chemistry
53. Co-targeting ASK1 and THRβ synergistically improves steatohepatitis and fibrosis in a MASH animal model
    Shu Shang, Qin Wan, Faxiu Chen, Jian Hu · 2024 · Biochemical and Biophysical Research Communications
54. Liver Stiffness in Obese Hypothyroid Patients Taking Levothyroxine
    Roberta Pujia, Elisa Mazza, Tiziana Montalcini, Franco Arturi, Antonio Brunetti, Antônio Aversa, Stefano Romeo, Maria Perticone, Angela Sciacqua, Arturo Pujia · 2022 · Medicina
55. Quantification of Thyromimetic Sobetirome Concentration in Biological Tissue Samples
    Jordan Devereaux, Skylar J. Ferrara, Thomas S. Scanlan · 2018 · Methods in molecular biology
56. Beyond resmetirom approval for NAFLD: what has to be done?
    Devaraj Ezhilarasan · 2024 · Drug Discovery Today
57. Evaluation of developmental and behavioral toxicity of Resmetirom in zebrafish larvae (Danio rerio)
    Yunfeng Shan, Zehong Chen, Anqi Guo, Zhengwei Huang, Zhengkang Su, Minjie Ye, Gaofeng Zhang, Xi Li, Chang Cai, Yin Dong · 2025 · Ecotoxicology and Environmental Safety
58. LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPA 1 ) ANTAGONISTS
    Peter T. W. Cheng, James R. Corte · 2025 · Medicinal chemistry reviews
59. RECENT ADVANCES, NEW DEVELOPMENTS, AND EMERGING OPPORTUNITIES IN DNA-ENCODED LIBRARY TECHNOLOGY
    Christian Nilewski, Moreno Wichert, James H. Hunter · 2025 · Medicinal chemistry reviews
60. Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Disease: Shared Mechanisms and Therapeutic Opportunities
    Daniel Basta, Assem H. Al Refaei, Linda Msinjili, William H. Frishman, Edward Lebovics · 2026 · Cardiology in Review
61. Mechanisms and reversal strategies of liver fibrosis: from regulation of cell fate to clinical translation
    Chuhan Zeng, Qiuxia Lu, Qi Zhao, Jian Li · 2026 · Journal of Translational Medicine
62. Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition
    James K. Hennan, Raul C. Camacho, Eric Solon, Brian Schmidt, Kevin French, Edward Chiang, Rebecca A. Taub · 2026 · Xenobiotica
63. Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
    Yao Zhang, Μaria Dalamaga, Junli Liu · 2022 · Metabolism Open
64. THR-β Agonist for Nonalcoholic Steatohepatitis Treatment: Challenges of a Promising Drug
    Feng Xue, Lai Wei · 2024 · Journal of Clinical and Translational Hepatology
65. Resmetirom Is an Effective Thyromimetics for the Chemical Rescue of Thyroid Hormone Receptor Mutants
    Mana Mitsutani, Mei Yokoyama, Hiromi Hano, Aoi Morita, Midori Matsushita, Tetsuya Tagami, Kenji Moriyama · 2025 · Biological and Pharmaceutical Bulletin
66. Metabolic, skeletal, and cartilage effects of a high-fat diet and the therapeutic impact of MGL3196 are age- and sex-dependent in mice
    O. Perez, G.A. Gomez, Chandrasekhar Kesavan, Bouchra Edderkaoui, A. Muralidharan, Sheila Pourteymoor, Adam Quincey, V. Franklin Sechriest, Subburaman Mohan · 2025 · Bone
67. An Alternate and Efficient Synthetic Process for a Metabolic Dysfunction-Associated Steatohepatitis Drug: Resmetirom
    Youbao Cui, Jiachen Zhang, Shuyu Liu, Zhenhang Zhao, Mengya Shan, Nan Jiang, Xin Zhai · 2025 · Organic Process Research & Development
68. Discovery of a Potent, Selective, and Multiple His435 Mutation-Sensitive Thyroid Hormone Receptor β Agonist
    Qiu Li, Benqiang Yao, Shiting Zhao, Zhou Lu, Xishan Wu, Zhi-fang Lu, Tong Wu, Junhua Li, Xiaoshan Chen, Zhiming Chen et al. · 2025 · Journal of Medicinal Chemistry
69. Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future
    Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal · 2025 · Diabetology International
70. Discovery of novel anti-fibrotics through phenotypic screening
    Alice Ruth Lapthorn, Sophie L. Harding, Kieran M. Feltham, Marcus Maximillian Ilg, Selim Cellek · 2025 · Drug Discovery Today
71. Design, synthesis, and biological evaluation of liver-targeting phosphoric acid thyroid hormone receptor agonists for the treatment of metabolic dysfunction-associated steatohepatitis
    Chao Lin, Peiwu Li, Yixing Zhang, Youyan Wei, Qiuyan Zhang · 2025 · Bioorganic Chemistry
72. Sappanone A, a potential natural inhibitor of PI3K, alleviates metabolic dysfunction-associated steatohepatitis in experimental models
    Xi Qiao, Qian Li, Ruiqi Fan, Yujie Cheng, Qingxuan Zeng, Huan Xue, Xiaoli Zhang, Yi Zhang, Yunfeng Liu · 2025 · Biochemical Pharmacology
73. Resmetirom: a first-in-class thyroid hormone receptor β agonist approved by FDA for patients with nonalcoholic steatohepatitis
    Xishan Wu, Qiuping Xiang, Yan Zhang, Yong Xu · 2025 · Elsevier eBooks
74. Effects of Resmetirom on Resistance to Thyroid Hormone Receptor Mutants: Potential Basis for Therapeutic Applications
    Mana Mitsutani, Hiromi Hano, Mei Yokoyama, Midori Matsushita, Tetsuya Tagami, Kenji Moriyama · 2025 · Biological and Pharmaceutical Bulletin
75. LEVERAGING PROTEIN TURNOVER IN DRUG DISCOVERY: A PRACTICAL GUIDE
    Jitao David Zhang, Neil John Parrott, Martin Ebeling, Miro Julian Eigenmann, Kenichi Umehara, Holger Fischer · 2025 · Medicinal chemistry reviews
76. A DRUG HUNTER’S APPROACH TO MOLECULAR GLUES
    Daniel S. La, Christopher G. Nasveschuk, Adam M. Gilbert · 2025 · Medicinal chemistry reviews
77. Resmetirom in the Management of MASLD: What Clinicians Need to Know
    Weiwei Xu, Manuel Romero‐Gómez, Vicente Artola Arita · 2025 · Current Hepatology Reports
78. The metabolic dysfunction-associated steatohepatitis (MASH) drug resmetirom exhibits broad nuclear receptor activity with minimal functional impact
    Annette Kärcher, Laura Isigkeit, Nils Christiaan Bandomir, Manfred Schubert‐Zsilavecz, Pascal Heitel · 2026 · Scientific Reports
79. Current therapeutic landscape and future treatment perspectives of MASH
    Suchira Gallage, Olivier Govaere, Quentin Mark Anstee, Gerald I. Shulman, Frank Tacke, Mathias F Heikenwälder · 2026 · Nature
80. Thyroid, Lipids, and Risk of Atherosclerosis
    Gabriela Brenta, Laura Ester Schreier · 2020 · Springer eBooks
81. Spezifische Therapie – neue Medikamente
    Naomi Franziska Lange, Jean‐François Dufour · 2022 · Springer eBooks
82. Therapeutic Approaches for Nonalcoholic Steatohepatitis ( NASH )
    Ralf Glatthar, Robert H. Arch · 2021 · Wiley eBooks
83. Metabolic dysfunction-associated steatotic liver disease in children
    Judith Lubrecht · 2025
84. A Pyridazinone Compound for Effectively Treating Non-alcoholic Steatohepatitis by Targeting THRβ
    Hao Cheng, Xiaobo Wang, Ying Zhi, Bo Liu, Na Liu, Mengjun Li, Yanling Mu · 2022 · Frontiers in Chemistry
85. Obesity Disrupts Pituitary UPR Leading to NAFLD
    Qingwen Qian, Mark Li, Zeyuan Zhang, Shannon William Davis, Kamal Rahmouni, Andrew W. Norris, Huojun Cao, Wen‐Xing Ding, Ling Yang · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
86. The significance of metabolism-associated steatotic liver disease and its treatment
    Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král · 2025 · Vnitřní lékařství
87. Resmetirom in metabolic dysfunction-associated steatohepatitis: a profile of its use
    Hannah A. Blair · 2025 · Drugs & Therapy Perspectives
88. Foie métabolique
    Antonio Saviano, Lawrence Serfaty · 2025 · EMC - Hépatologie
89. Targeting PKLR and lipogenic enzymes through JNK inhibition to develop a therapeutic strategy for MASLD and MASH
    Adil Mardinoğlu, Woonghee Kim, Mengzhen Li, Xinmeng Liao, Sevilay Özmen, Edanur Yıldız, Melik Saraçoğlu, Cem Baba, Fatih Çağlar Çelikezen, Said Ali Atalay et al. · 2025 · Research Square
90. Agonisti selettivi del recettore $\beta $ degli ormoni tiroidei nel trattamento dell’epatopatia cronica su base dismetabolica
    Giordano Paolucci, Alessio Basolo, Paola Fierabracci, Ferruccio Santini · 2025 · L Endocrinologo
91. NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2024
    David W. Lin, Megan Armstrong, Jennifer Bo Jiang, Renyu Guo, Christiana N. Teijaro, Tobias Sandmeier · 2025 · Medicinal chemistry reviews
92. THE PRIVILEGE OF MAKING A DIFFERENCE IN DEVELOPING AND DELIVERING MEDICINES
    Taiyin Yang · 2025 · Medicinal chemistry reviews
93. RECENT ADVANCES IN SMALL-MOLECULE THERAPEUTICS TARGETING NEUROINFLAMMATION
    René Rahimoff, Marko Nesic · 2025 · Medicinal chemistry reviews
94. CASE HISTORY: DISCOVERY AND DEVELOPMENT OF THE PI3Kδ-SELECTIVE INHIBITOR JOENJA ® (LENIOLISIB, CDZ173) AS A TARGETED THERAPY FOR PATIENTS WITH ACTIVATED PI3Kδ SYNDROME (APDS)
    Klemens Hoegenauer, Nicolas Soldermann, Christoph Burkhart, Christoph Kalis · 2025 · Medicinal chemistry reviews
95. ADVANCES IN SMALL-MOLECULE–BASED THERAPIES AGAINST HUMAN PATHOGENIC FREE-LIVING AMOEBAE
    Julia M. Pomeroy, Seoyoung Kim, Jennifer E. Golden · 2025 · Medicinal chemistry reviews
96. TO MARKET, TO MARKET—2024: SMALL MOLECULES
    Sarah Anthony, Erika Araujo, Björn Bartels, Marco Brandstätter, Christopher J. Bungard, Georgette M. Castanedo, T. G. Murali Dhar, Natalie Holmberg‐Douglas, Renyu Guo, Jeremy M. Richter et al. · 2025 · Medicinal chemistry reviews
97. SMALL-MOLECULE M 1 AND M 4 ACTIVATORS FOR THE TREATMENT OF COGNITIVE IMPAIRMENT AND PSYCHOSIS
    Brian Ngo Laforteza, Michael Rombola, Usha Viswanathan · 2025 · Medicinal chemistry reviews
98. Table of Contents, Contributor List, Preface
    2025 · Medicinal chemistry reviews
99. NEW KIDS ON THE BLOCK: PROXIMITY-BASED MODALITIES AS ANTIVIRAL THERAPIES
    Isaac D. Falk, Rhiannon Thomas‐Tran · 2025 · Medicinal chemistry reviews
100. CASE HISTORY: TRUQAP® (CAPIVASERTIB) WITH FULVESTRANT FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA/AKT1/PTEN-ALTERATIONS
     Jason G. Kettle, Elza C. de Bruin, Andrew Foxley, Gaia Schiavon, Simon T. Barry · 2025 · Medicinal chemistry reviews